Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma

Federico Pasin1, Matteo Mascalchi Calveri2, Alberto Calabrese3

  • 1Internal Medicine Unit,ASST Cremona. f.pasin@asst-cremona.it.

Insights

COVID-19 infection may transiently reduce Natural Killer (NK) lymphoma cells and symptoms. This viral illness potentially triggers an enhanced anti-tumor immune response, leading to temporary remission in NK neoplasms.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Natural Killer (NK) cells play a role in lymphoma immunity.
  • NK/T-cell lymphoma is often associated with Epstein-Barr virus (EBV).
  • COVID-19 (caused by SARS-CoV-2) affects various immune cells, including NK cells expressing ACE2.

Observation:

  • A patient with refractory NK/T-cell lymphoma experienced transient remission during COVID-19 pneumonia.
  • During COVID-19, a decrease in NK cells and plasma EBV-DNA (a lymphoma marker) was observed.
  • Following COVID-19 resolution, lymphoma relapse occurred with increased NK cells and EBV-DNA.

Findings:

  • COVID-19 infection may transiently suppress NK cell function and reduce lymphoma burden.
  • SARS-CoV-2 binding to ACE2 on NK cells could contribute to their dysfunction.
  • Proinflammatory cytokines during COVID-19 might induce lymphodepletion, impacting lymphoma.

Implications:

  • This case suggests a potential link between viral infections and spontaneous remission in certain cancers.
  • Understanding the immune response to concurrent viral infections could offer novel therapeutic strategies for NK lymphoma.
  • Further research is needed to elucidate the mechanisms behind virus-induced anti-tumor effects.